Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative disorders

This page shows the latest neurodegenerative disorders news and features for those working in and with pharma, biotech and healthcare.

Axovant licenses another gene therapy as new strategy beds in

Axovant licenses another gene therapy as new strategy beds in

According to Wright, this ‘silence and replace’approach is unique in gene therapy and “could be an elegant solution to tackling autosomal dominant genetic disorders”– in other words diseases caused even ... In neurology that includes a number

Latest news

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    R&D collaboration and option to acquire. Molecules targeting mitochondrial function to treat genetic, metabolic or neurodegenerative disorders (discovery).

  • Lonafarnib: promising results in first-ever trial for progeria Lonafarnib: promising results in first-ever trial for progeria

    FTIs are also in very early development in Alzheimer's disease and neurodegenerative disorders: AstraZeneca has a preclinical research programme in neurodegenerative disease therapeutics and OSI 754 is in phase I

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... Dr Mikael Dolsten, president of

  • Minoyrx Therapeutics appoints chief medical officer Minoyrx Therapeutics appoints chief medical officer

    He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders. ... Prior to this, Dr Meya was

  • Chase Pharmaceuticals appoints former Allergan president Chase Pharmaceuticals appoints former Allergan president

    As CEO, Ingram will focus on the direction of Chase Pharmaceuticals' development and commercialisation of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer's

  • Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

    phase III clinical programme targeting a genetically-defined Alzheimer's disease population, and execute on our long-term strategy to bring innovative therapies to patients with neurodegenerative disorders.”.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics